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Background: Although the expenses of liver cirrhosis are covered by a critical illness fund under the current health
insurance program in China, the economic burden associated with hepatitis B virus (HBV) related diseases is not
well addressed. In order to provide evidence to address the economic disease burden of HBV, we conducted a
survey to investigate the direct economic burden of acute and chronic hepatitis B, cirrhosis and liver cancer caused
by HBV-related disease.
Methods: From April 2010 to November 2010, we conducted a survey of inpatients with HBV-related diseases and
who were hospitalized for seven or more days in one of the seven tertiary and six secondary hospitals in
Shandong, China. Patients were recorded consecutively within a three-to-five month time period from each
sampled hospital; an in-person survey was conducted to collect demographic and socio-economic information, as
well as direct medical and nonmedical expenses during the last month and last year prior to the current
hospitalization. Direct medical costs included total outpatient, inpatient, and self-treatment expenditures; direct
nonmedical costs included spending on nutritional supplements, transportation, and nursing. Direct medical costs
during the current hospitalization were also obtained from the hospital financial database. The direct economic
cost was calculated as the sum of direct medical and nonmedical costs. Our results call for the importance of
implementing clinical guideline, improving system accountability, and helping secondary and smaller hospitals to
improve efficiency. This has important policy implication for the on-going hospital reform in China.
Results: Our data based on inpatients with HBV-related diseases suggested that the direct cost in US dollars for
acute hepatitis B, severe hepatitis B, chronic hepatitis B, compensated cirrhosis, decompensated cirrhosis and
primary liver cancer was $2954, $10834, $4552, $7400.28, $6936 and $10635, respectively. These costs ranged from
30.72% (for acute hepatitis B) to 297.85% (for primary liver cancer) of the average annual household income in our
sample. Even for patients with health insurance, direct out-of-pocket cost of all HBV-related diseases except acute
hepatitis B exceeded 40.00% of the patient’s disposable household income, making it a catastrophic expenditure for
the household.
Conclusion: Hepatitis B imposes considerable economic burden on a family. Our findings will help health policy
makers’ understanding of the magnitude of the economic burden of HBV-related diseases in China. Evidence from
our study also contributes to our understanding of potential benefits to society from allocating more resources to
preventing and treating HBV infection, as well as increasing insurance coverage in China. These findings have
important policy implications for health care reform efforts currently underway in China focusing on how to reduce
the burden of catastrophic disease for its citizens.* Correspondence: wangjiannan@sdu.edu.cn
2Shandong Center for Disease Control and Prevention, Jinan, Shandong
250014, China
Full list of author information is available at the end of the article
© 2013 Lu et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.




Acute hepatitis B B16.902 Acute hepatitis B
without icteric
B16.901 Acute hepatitis B with
icteric
Severe hepatitis B B16.906 Severe hepatitis B
B16.908 Acute Severe hepatitis B
B16.909 subacute severe
hepatitis B
B18.102 Chronic severe hepatitis B
Compensated and
decompensated cirrhosis
K74.601 cirrhosis of liver
Primary liver cancer C22.001 Hepatocellular
carcinoma
Lu et al. BMC Health Services Research 2013, 13:37 Page 2 of 8
http://www.biomedcentral.com/1472-6963/13/37Background
According to the fourth national socio-epidemiological
survey, the prevalence of hepatitis B surface antigen
among Chinese aged less than 60 was 7.20% in 2006 [1].
At present, there is no cure for chronic hepatitis B (CHB)
related disease and its complications. Clinicians mainly
adopt antiviral treatment or immunomodulatory methods
to improve liver function, and anti-fibrosis treatment to
slow down the progression of the disease. The nature of
lasting and recurring conditions from HBV infection com-
pounded by the frequency of delayed consultation impose
a heavy economic burden on patients with HBV and their
families. It is therefore of great policy interest whether
health insurance in China is adequate in terms of redu-
cing the economic burden for those with chronic HBV.
Although the direct economic burden of CHB in China
has been estimated in a few studies [2–6], none of these
studies estimated the direct out-of-pocket cost of all
HBV-related diseases, including acute hepatitis B, severe
hepatitis B, chronic hepatitis B, compensated cirrhosis, de-
compensated cirrhosis, and primary liver cancer.
In order to fill this gap, we conducted a survey and
collected information on patients from thirteen repre-
sentative hospitals in Shandong, China to investigate the
direct costs of HBV-related diseases and their impact on
households. This study aimed to provide evidence that
would contribute to our understanding of the potential
benefits to society of allocating more resources to pre-
venting and treating HBV infection, as well as expanding
insurance coverage for those with HBV-related diseases
in China. This research has important policy implica-
tions for ongoing health care reform in China aimed at
reducing the economic burden of catastrophic disease
for its citizens.
Methods
Study population: the Shandong HBV-related inpatient
economic burden survey
Between April and November 2010, we conducted a
hospital survey of inpatients with HBV-related diseases in
Shangdong province, China. We first used information
from the Major Epidemic Network database to identify
hospitals in all seventeen cities in Shandong which treated
HBV-related patients in 2010. The Department of Health’s
National Centre for Disease Control requires all hospitals
in China to provide monthly reports of patients hospita-
lized for the treatment of HBV-related illness to the Major
Epidemic Network. All 17 prefecture Centers for Disease
Control and Prevention in Shandong province have been
required to regularly report number of cases with hepatitis
B virus related disease through the National Notifiable
Disease Surveillance System (NNDSS). This information
in the NNDSS was used to partly guide our data sampling.
First, out of the prefectures with the largest reportednumber of cases in NNDSS, we chose three prefectures –
Qingdao, Jinan, and Liaochang – as representative prefec-
tures of the province. Geographically, these prefectures
are located in the east, central, and west part of the prov-
ince. Each represents different level of economic develop-
ment: west being the most, central next, and east the
least developed. Then, within each chosen prefecture, two
tertiary or secondary hospitals were randomly chosen.
Finally, our interviewers went sent to these selected hospi-
tals to conduct the survey in September 2010.
In our survey, ICD-10 was used to identify eligible cases
(Table 1). Inpatients were recorded consecutively within a
time period of three to five months from each of the thir-
teen sampled hospitals. Patient sampling was ended when
the number of qualified observations reached 400 in each
city, except in Liaocheng where the patients totaled less
than 200. Patients eligible to be included in the survey
included those who were admitted into a hospital for
seven or more days due to HBV-related disease and its
complications, including acute hepatitis B, severe hepatitis
B, chronic hepatitis B, compensated cirrhosis, decompen-
sated cirrhosis, and primary liver cancer. The diagnostic
standard in this paper for severe hepatitis B is: Prothrom-
bin activity below 40% and serum bilirubin more than 10
times normal. We excluded patients with toxic, drug
induced and immune hepatic disease, viral hepatitis
caused by a secondary liver virus, as well as patients with
HBV-related diseases whose hospitalization was for an-
other reason. This resulted in a total of 949 observations
in three cities (Figure 1).
Interviews were conducted by 10 trained professional
investigators to collect information on both outpatient
and inpatient expenses during the 12 months prior to the
current hospitalization. The interviewers were six post-
graduate students of the Centre for Health Management
and Policy at Shandong University whose major was social
949 inpatients meeting inclusion criteria
A total of 894 inpatients were observed 
from three cities
Initial list of inpatients potentially eligible 
for inclusion.
A Total of 111 inpatients were excluded as 
they did not meet inclusion criteria
55 inpatients excluded: 45 did not receive 
survey, 2 were in critical condition, 7 
hospitalized for other reason, 1 was 
excluded for hospital stay.
1061 inpatients, including alcoholic hepatitis, 
Autoimmune hepatitis, drug-induced 
hepatitis, hepatitis C, hepatitis E and inpatients 
whose duration of hospital stay <= days in 
secondary hospitals.
Figure 1 A summary of sampling participants for interview.
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members who were trained in public health with a spe-
cialty in epidemiology at the Shandong Provincial Centre
for Disease Control and Prevention. Investigators explained
the purposes and confidentiality of the survey, and then
invited patients to participate in the survey. Respondents
could choose not to participate; 894 agreed to be inter-
viewed. Ethics approval of this study was obtained from
the Shandong Provincial Centre for Disease Control
and Prevention. After patients were discharged from the
hospital, inpatient expenses for the most recent hospitali-
zation were obtained from the hospital financial database.
Key variables
In the survey, the following information was collected:
hospital ID, demographic information and socioeconomic
status (including age, gender, education, occupation, family
size, and individual and household monthly income), diag-
nosis (ICD-10), and health insurance status. ICD-10 is col-
lected from the hospital nursing stating where patients are
diagnosed when admission. Therefore the interviewers
would have had that information ahead of time. Health in-
surance was categorized as insured or uninsured. Insured
was defined as someone who was covered by any of the fol-
lowing types of health insurance programs: public insur-
ance provided to civil servants, the basic health insurance
scheme for urban employees (BHISUE) or for urban re-
sidents (BHISUR), the New Rural Cooperative Medical
Scheme (NRCMS), or private insurance.
The patients were interviewed during hospitalization
about their expenditures of previous hospital stays within
the last 12 months. The expenditures of their current
hospital stays were extracted directly from the hospital fi-
nancial database right after their discharge. Direct medical
costs included total outpatient and inpatient expenditures
(i.e., hospitalization expenditures, nursing, prescription
drugs, examination fees, etc.), and total self-treatment
expenditures. Direct total costs for each patient were
divided by the number of admissions if the patient hadtwo or more hospital admissions. Direct nonmedical costs
included expenditures on nutrition supplements, trans-
portation, and patient accompaniers’ costs as a result of
the disease. Finally, information on inpatient expenditures
for the current hospitalization was obtained from the hos-
pital financial database. All costs are expressed in United
States dollars using the June 30, 2010 exchange rate of
6.7909 RMB.
Statistical analysis
Descriptive statistics were employed to illustrate the char-
acteristics of both insured and uninsured patients in the
study population; the characteristics included sociodemo-
graphic characteristics, out-patient and inpatient expenses,
direct and in-direct costs, and health insurance status.
Frequencies of variables in the survey were not weighted
because sampling weights were not available. A parallel
and double entry method was used to input data using
Epidata 3.0; direct medical and nonmedical costs were cal-
culated. Stata 7.0 was used for the statistical analysis in
this study. As the costs were non-normally distributed,




A descriptive analysis of both insured and uninsured
HBV-related patients is provided in Table 2. Among the
894 HBV-related patients included in our survey, 347
cases were from Jinan, 374 cases from Qingdao and 173
cases from Liaocheng. There were 849 patients (94.97%)
with insurance; 45 (5.03%) without insurance. Most
patients (86.35%) had one of three conditions: chronic
hepatitis B, compensated cirrhosis or decompensated
cirrhosis. Mean age was 45.80 years and over two-thirds
were male (641 or 71.70%). The insured group was older
than the uninsured group (46.37 vs. 34.89). Most had
obtained a high school education or above; only 19.69%
were uneducated or only attended primary school.
Table 2 Characteristics of all HBV-related diseases for insured and uninsured inpatients in Shandong province
Characteristics All inpatients Uninsured (%) Insured (%)
N = 894 N = 45 N = 849
Location
Jinan 347 5.19 94.81
Qingdao 374 5.89 94.11
Liaocheng 173 2.89 97.11
Condition
Acute hepatitis B 29 4 (13.79%) 25 (86.21%)
Severe hepatitis B 28 0 (0.00%) 28 (100.00%)
Chronic hepatitis B 449 33 (7.35%) 416 (92.65%)
Compensated cirrhosis 121 1 (0.83%) 120 (99.17%)
Decompensated cirrhosis 202 6 (2.97%) 196 (97.03%)
Primary liver cancer 65 1 (1.54%) 64 (98.46%)
Male 71.7% 80 71.26
Age (sd) 45.8 (13.88) 34.89 (12.04) 46.37 (13.73)
Education
Uneducated and primary school 19.69 8.89 20.26
High school 60.74 57.78 60.90
College 18.57 28.89 18.02
Graduate 1.01 4.44 0.82
household monthly income (sd) 438 (464) 411 (325) 439 (470)
Patient monthly income (sd) 190 (201) 191 (220 ) 190 (201)
*Notes:
1. Monetary values reported in US dollars. 1 US dollar = 6.7909 RMB (exchange rate on Jun 30th, 2010).
2. Standard deviation is reported in the parentheses.
Table 3 Inpatient direct costs of all HBV-related diseases
(dollar/per admission)
Classification Direct cost
Insured Uninsured Overall mean
acute hepatitis B 3098 2056 2954
severe hepatitis B 10834. - 10834
chronic hepatitis B 4689 2825 4552
compensated cirrhosis 7451 1311 7400
decompensated cirrhosis 7046 3359 6937
primary liver cancer 10769 2099 10636
x2 127.87 3.66 135.47
P 0.0001 0.4538 0.0001
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sample; $439 for the insured and $411 for the unin-
sured group. Individual monthly income was $190 for
the overall sample; $190 for the insured and $191 for
the uninsured.
Direct cost
Direct total costs for each patient were divided by the
number of admissions if the patient had two or more
hospital admissions. As shown in Table 3, the direct
costs for acute hepatitis B, severe hepatitis B, chronic
hepatitis B, compensated cirrhosis, decompensated cir-
rhosis, and primary liver cancer were $2954, $10834,
$4552, $7400, $6937, and $10636 respectively. Direct
costs for inpatients who were insured were higher than
for the uninsured. Proportion of direct medical cost (%)
is consistently high, accounting for 91-97% in direct
cost. For insured patients, there was a significant differ-
ence in the direct costs among the HBV-related diseases
with primary liver cancer costing much more.
The direct medical cost of acute hepatitis B, severe
hepatitis B, chronic hepatitis B, compensated cirrhosis,
decompensated cirrhosis, and primary liver cancer was
$2854, $10114, $4136, $6781, $6400, and $9891,respectively. As shown in Table 4, outpatient expendi-
tures were highest for primary liver cancer ($1476), fol-
lowed by decompensated cirrhosis and compensated
cirrhosis at $958 and $951, respectively. Hospitalization
stay expenditures were highest for severe hepatitis B and
primary liver cancer, $9367 and $8209 respectively, fol-
lowed by compensated cirrhosis and decompensated
cirrhosis, $5762 and $5355, respectively. As for self-
treatment expenditures, primary liver cancer and severe
Table 4 Direct medical cost of all HBV-related diseases (dollar/per annual average admission)
Classification Outpatient expenditure Hospitalization stay expenditure Self-treatment expenditure Total
Acute hepatitis 109 2741 4 2854
B (median) (60) (2332) (0) (2363)
Severe hepatitis 557 9367 191 10114
B (median) (265) (9395) (0) (9426)
Chronic hepatitis 615 3508 13 4136
B (median) (133) (2215) (0) (2745)
Compensated 951 5762 67 6781
cirrhosis (median) (996) (3152) (0) (3811)
Decompensated 958 5355 88 6400
cirrhosis (median) (305) (3754) (0) (4541)
Primary liver 1476 8209 206 9891
cancer (median) (449) (5941) (0) (7260)
x2 41.87 126.01 24.76 131.63
P 0.0001 0.0001 0.0002 0.0001
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$191, respectively. Uninsured patients reported almost
no self-treatment expenses. For insured patients, direct
medical costs differed significantly among the six HBV-
related conditions, with the highest spending being for
severe hepatitis B ($10114. Clearly this disease has a
major impact in terms of healthcare costs.
The study found that the direct nonmedical cost of
acute hepatitis B, severe hepatitis B, chronic hepatitis B,
compensated cirrhosis, decompensated cirrhosis and pri-
mary liver cancer, was $100, $719, $416, $619, $536 and
$745. Transportation costs were $83, $537, $113,$235,
$230 and $494, respectively, and were higher for insured
versus uninsured patients.. Nutrition expenses were $16,
$170, $302, 383, $303 and $251, respectively. There were
no statistically significant differences in the direct non-
medical cost of HBV-related diseases among those who
did not have insurance. However, direct nonmedical
costs of those who had insurance were highest for
patient’s primary liver cancer.Impact of disease burden on a household
The direct economic burden of HBV-related diseases
and their impact on a household were illustrated in
Table 5. The direct cost of HBV-related diseases as a
proportion of annual family income ranged from 30.72%
for those with acute Hepatitis B to 297.85% for those
with primary liver cancer. Even after reimbursement, the
direct cost of patients who experienced severe hepatitis
B, chronic hepatitis B, compensated cirrhosis, decom-
pensated cirrhosis, and primary liver cancer exceeded
40.00% of disposal household income. The economicburden was significantly different among the six diseases
for insured patients.
Re-analyses after excluding the 45 uninsured patients
We re-ran the analyses after excluding the 45 uninsured
patients since some of the conditions were either not
represented (severe hepatitis B) or have very few patients
(acute hepatitis B, compensated cirrhosis, primary liver
cancer) among uninsured patients (Table 2). In this ana-
lysis, costs were stratified by level of care since costs
may differ between tertiary and secondary hospitals.
As shown in Table 6, the direct cost for acute hepatitis
B, severe hepatitis B, chronic hepatitis B, compensated
cirrhosis, decompensated cirrhosis, and primary liver
cancer in tertiary hospitals was $3135, $10834, $4380,
$6022, $7107, and $10213 respectively. The direct cost
for acute hepatitis B, chronic hepatitis B, compensated
cirrhosis, decompensated cirrhosis, and primary liver
cancer in secondary hospitals was $1388, $5588, $19919,
$6565, and $13268, respectively. The direct costs for
acute hepatitis B were significantly higher in tertiary
hospitals compared to secondary hospitals (x2 = 4.31,
P = 0.0378), whereas the opposite was true for those with
chronic hepatitis B (x2 = 12.12, P = 0.0005).
As shown in Table 6, median cost of patients with acute
hepatitis B treated in secondary hospitals is significantly
lower than those treated in tertiary hospitals (1388 vs.
3135, p < 0.04). ). It should be noted, however, that the
sample size of patients with acute hepatitis B treated in
secondary hospitals is quite low (3 only) and the results
on cost comparison may not be meaningful. For patients
with chronic hepatitis B however, 64 were treated in sec-
ondary hospitals and 385 in tertiary hospitals. The median
Table 5 The impact of disease burden on a household (dollar/per annual average admission)












3098 1549 2056 2954 10171 6141 9615 30.46 15.23 33.48 30.72
(2779) (1389) (1469) (2464) (5301) (5213) (5301) (52.42) (26.21) (28.18) (46.49)
severe hepatitis
B (median)
10834 5417 — 10834 3941 — 3941 274.89 137.45 — 274.89
(9699) (4849) (9697) (3534) (3534) (274.42) (137.20) (174.39)
chronic hepatitis
B (median)
4689 2345 2825 4552 5824 5191 5778 80.52 40.26 54.42 78.79
(2978) (1489) (2673) (2919) (4418) (4241) (4418) (67.41) (33.70) (63.02) (66.07)
compensated
cirrhosis (median)
7451. 3726 1311 7400 5297 3534 5282 140.67 70.34 37.09 140.10
(4116) (2058) (0.00) (4074) (3711) (3534) (3711) (110.93) (55.46) (37.09) (109.77)
decompensated
cirrhosis (median)
7046 3523 3359 6937 4187 3475 4166 168.30 84.15 96.65 166.52
(4980) (2490) (3423) (4946) (3534) (2474) (3534) (140.91) (70.45) (138.37) (139.95)
primary liver
cancer (median)
10769 5385 2099 10636 3602 1590 3571 298.99 149.50 131.99 297.85
(7977) (3988) (2099) (7884) (2827) (1590) (2827) (282.15) (141.06) (131.99) (278.86)
x2 127.87 127.00 3.66 135.47




















Table 6 The direct cost of all HBV-related diseases stratified by hospitals (dollar/per average annual admission)
Classification Tertiary hospitals Secondary hospitals Total x2 P
NO. cost NO. cost NO. cost
Acute hepatitis B (median) 26 3135 3 1388 29 2954 4.31 0.0378
(2830) (1598) (2464)
Severe hepatitis B (median) 28 10834 0 — 28 10834 — —
(9697) 449 (9697)
Chronic hepatitis B (median) 385 4380 64 5588 4552 12.12 0.0005
(3012) (2131) (2919)
Compensated cirrhosis (median) 109 6022 12 19919 121 7400 0.08 0.7747
(3909) (4586) (4074)
Decompensated cirrhosis (median) 170 7107 32 6565 202 6937 1.99 0.1583
(5042) (4177) (4946)
Primary liver cancer (median) 56 10213 9 13268 65 10636 1.39 0.2390
(7595) (11223) (7884)
x2 115.20 21.99 135.47
P 0.00 0.00 0.0001
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higher (5588 vs. 4380, p < 0.00).
Discussion
Even with health insurance coverage, the direct costs of
HBV-related diseases, except acute hepatitis B, exceeded
40.00% of household annual income in China, suggesting
that HBV-related diseases should be placed categorized
as catastrophic [7,8]. Due to the large amount of eco-
nomic resources consumed, our results indicate that
HBV-related diseases imposed a substantial economic
burden on patients and their families in China [9,10].
Our findings demonstrate that the direct economic
burden of HBV infection increases as the disease pro-
gresses, with severe hepatitis B and primary liver cancer
incurring expenses close to three times annual house-
hold income. By far the largest portion of direct costs,
over 90 per cent, were medical in nature, consistent with
Li et al.’s findings that 93.07% of direct costs were med-
ical [6]. Much of the direct medical costs (84.86%) were
due to the costs of hospitalization, mainly due to drugs
and examination fees which accounted for 77.49% of
hospitalization costs.
Our study has several limitations. First, only tertiary
and secondary hospitals were included in our survey. No
township hospitals were sampled because the number of
patients with HBV-related diseases in these hospitals
was very small. Second, other than the direct medical
cost for the current hospitalization, which was obtained
from hospital financial data, all other outpatient and in-
patient costs were self-reported and may be subject to
recall error. Third, our data only allowed us to assess the
direct inpatient cost of HBV-related diseases. We didnot have data to estimate the direct outpatient cost of
HBV-related diseases, nor were we able to evaluate the
indirect cost of HBV-related diseases such as loss of
productivity and income as a result of illness days and
hospitalization, or loss of income for family members
who were caregivers. In other words, the actual total
economic burden of HBV-related diseases could be ei-
ther higher or lower than our estimates. On the other
hand, however, our survey only included patients who
were hospitalized for seven or more days. These are
likely patients with higher severity of illness which would
cause upward bias in our estimations. Finally, our study
does not capture the full burden of disease because it
does not survey individuals infected with hepatitis B
who were not hospitalized during the sampling period.
Future research should address the important issue of
estimating the overall economic burden of HBV-related
diseases in China.
Our data indicated that median cost of chronic hepatitis
B patients in secondary hospitals was significantly higher
than those in tertiary hospitals. Considering the fact that
patients with more severe illnesses and thus more costly
patients would have been more likely to seek treatment at
tertiary hospital, this result is alarming. This might be an
indication of higher level of inefficiencies among second-
ary hospitals, as compared with tertiary hospitals. Clinical
guideline is still under development in China, and hospital
inefficiency has been a huge concern in the current
hospital system. While tertiary hospitals attract the best
resources, secondary hospitals in China are in a much
more disadvantaged position and as a result, quality of
care and efficiency could be much bigger issues. Our
results call for the importance of implementing clinical
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secondary and smaller hospitals to improve efficiency.
This has important policy implication for the on-going
hospital reform in China.
Conclusion
Hepatitis B imposes considerable economic burden on a
family. Our findings will help health policy makers’ under-
standing of the magnitude of the economic burden of
HBV-related diseases in China. Evidence from our study
also contributes to our understanding of the potential ben-
efits to society of allocating more resources to preventing
and treating HBV infection, as well as increasing insurance
coverage in China. For instance, patients with severe hepa-
titis B or primary liver cancer suffered a high economic
burden even after insurance reimbursement, spending
137.45% and 149.50%, respectively, of their household an-
nual income. These findings have important policy impli-
cations for health care reform efforts currently underway
in China focusing on how to reduce the burden of cata-
strophic disease for its citizens. In addition, overtreatment
and over-medication are among the reasons for high per-
sonal costs in private facilities, given that government
funding to public providers is insufficient. It is important
to note that funds currently used for the unnecessary
treatment of acute hepatitis B and for nutrition supple-
ments could be redirected to programs designed to reduce
the economic burden of HBV-related diseases.
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